Based on the analysis of the component‐target‐pathway network, we screened MAPK1, MAPK3, MAPK14 and EGFR as key targets, indicating that the role of dapagliflozin‐mediated therapy in the treatment of T2DM complicated with CVD might be mainly associated with above targets. This evidence concerns the gene MAPK1 and type 2 diabetes mellitus.